KIT and gastrointestinal stromal tumor: Imatinib mesylate, a small‐molecule tyrosine kinase inhibitor (TKI), is utilized as the primary therapy for GIST since its ability for targen ted inhibition of KIT.[3] IM improved the prognosis of patients significantly, with disease control observed in 70% to 85% of patients.